Sam Brusco, Associate Editor08.31.23
Radiaction Medical, a company aiming to provide radiation protection to medical staff during interventional procedures, has made two announcements.
First, the company raised $12.6 million in Series C2 funding, led by InnovaHealth Partners and with participation from other investors. Second, the company elected Christopher Barys to its board of directors. Barys brings over 30 years of medical device sales experience to Radiaction, including within the cardiac catheterization and image-guided spaces.
According to the company, the Radiaction system is the first, only advanced tech to proactively block radiation at the source for comprehensive, head-to-toe radiation protection to the entire interventional team. This is all while allowing unencumbered patient care, access, and service.
Radiaction is a plug-and-play addition to C-arm systems that dynamically, proactively blocks up to 97% of scatter radiation at the source. The technology has both CE marking and U.S. Food and Drug Administration (FDA) clearance.
The company said Radiaction is clinically supported, with extensive lab testing and real-world, peer-reviewed, published literature validating its performance.
Barys told the press, “I am thrilled to be a part of Radiaction’s mission to provide advanced radiation protection to the entire procedural staff. Now more than ever, the medical community needs innovative solutions to pressing systemic problems. Radiaction is disrupting the industry for the better. I am looking forward to supporting Radiaction in bringing its radiation reduction solution to every catheterization lab in the U.S. and abroad.”
Radiaction is quickly expanding its U.S. footprint, adding new sites to its user base, offering key support staff to ensure success of each system installation, developing additional features, and growing its clinical publication pipeline to support the tech’s performance with clinical data.
First, the company raised $12.6 million in Series C2 funding, led by InnovaHealth Partners and with participation from other investors. Second, the company elected Christopher Barys to its board of directors. Barys brings over 30 years of medical device sales experience to Radiaction, including within the cardiac catheterization and image-guided spaces.
According to the company, the Radiaction system is the first, only advanced tech to proactively block radiation at the source for comprehensive, head-to-toe radiation protection to the entire interventional team. This is all while allowing unencumbered patient care, access, and service.
Radiaction is a plug-and-play addition to C-arm systems that dynamically, proactively blocks up to 97% of scatter radiation at the source. The technology has both CE marking and U.S. Food and Drug Administration (FDA) clearance.
The company said Radiaction is clinically supported, with extensive lab testing and real-world, peer-reviewed, published literature validating its performance.
Barys told the press, “I am thrilled to be a part of Radiaction’s mission to provide advanced radiation protection to the entire procedural staff. Now more than ever, the medical community needs innovative solutions to pressing systemic problems. Radiaction is disrupting the industry for the better. I am looking forward to supporting Radiaction in bringing its radiation reduction solution to every catheterization lab in the U.S. and abroad.”
Radiaction is quickly expanding its U.S. footprint, adding new sites to its user base, offering key support staff to ensure success of each system installation, developing additional features, and growing its clinical publication pipeline to support the tech’s performance with clinical data.